Literature DB >> 517258

Altered urinary excretion of human kininase activity in hypertension.

A Greco, G Porcelli, M Di Jorio, M Ranieri, L D'Acguarica, L Ranalli.   

Abstract

This study describes the levels of urinary kininase activity in hypertension. Urinary kininase activity in essential and secondary hypertensive patients was higher than in controls (1010.2 +/- 102.7 versus 114.4 +/- 23.1 ng destroyed bradykinin/min.; p less than 0.001). In a group of hypertensive diabetics without nephropathy kininase activity in urine was decreased (46.0 +/- 12.7 ng destroyed bradykinin/min.). This investigation shows that in hypertension urinary kininase activity reaches higher levels. An inverse correlation was found between urinary kallikrein and urinary kininase activity from essential hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 517258

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  2 in total

1.  Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study.

Authors:  Yongxian Hu; Yali Zhou; Mingming Zhang; Houli Zhao; Guoqing Wei; Wengang Ge; Qu Cui; Qitian Mu; Gong Chen; Lu Han; Tingting Guo; Jiazhen Cui; Xiaoyan Jiang; Xiujun Zheng; Shuhui Yu; Xiaolong Li; Xingwang Zhang; Mingxi Chen; Xiuju Li; Ming Gao; Kang Wang; Cheng Zu; Hao Zhang; Xiaohong He; Yanbin Wang; Dongrui Wang; Jiangtao Ren; He Huang
Journal:  Cell Res       Date:  2022-09-23       Impact factor: 46.297

2.  Urinary kallikrein excretion in type 1 (insulin-dependent) diabetes mellitus.

Authors:  A Manto; P Cotroneo; G Porcelli; G D'Errico; G Marra; P Magnani; P Tilli; A V Greco; G Ghirlanda
Journal:  Diabetologia       Date:  1993-05       Impact factor: 10.122

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.